Anna Wrona

1.4k total citations
34 papers, 692 citations indexed

About

Anna Wrona is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Anna Wrona has authored 34 papers receiving a total of 692 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in Anna Wrona's work include Lung Cancer Treatments and Mutations (14 papers), Lung Cancer Research Studies (7 papers) and Lung Cancer Diagnosis and Treatment (7 papers). Anna Wrona is often cited by papers focused on Lung Cancer Treatments and Mutations (14 papers), Lung Cancer Research Studies (7 papers) and Lung Cancer Diagnosis and Treatment (7 papers). Anna Wrona collaborates with scholars based in Poland, Switzerland and United States. Anna Wrona's co-authors include Jacek Jassem, Rafał Dziadziuszko, D. Ross Camidge, Solange Peters, Silvia Novello, Ewa Lewicka, Grzegorz Raczak, Alice T. Shaw, Tony Mok and D.W. Kim and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and International Journal of Molecular Sciences.

In The Last Decade

Anna Wrona

32 papers receiving 681 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anna Wrona Poland 12 519 449 180 96 53 34 692
Joan Lucca United States 12 753 1.5× 683 1.5× 196 1.1× 62 0.6× 55 1.0× 25 1.0k
Karin Holmskov Hansen Denmark 13 801 1.5× 622 1.4× 233 1.3× 160 1.7× 78 1.5× 34 945
Chiara Bennati Italy 13 502 1.0× 406 0.9× 180 1.0× 158 1.6× 17 0.3× 40 632
Fernando C. Santini United States 13 464 0.9× 685 1.5× 211 1.2× 143 1.5× 59 1.1× 34 958
Sasja F. Mulder Netherlands 12 340 0.7× 253 0.6× 265 1.5× 130 1.4× 70 1.3× 38 669
Nuria Kotecki Belgium 13 284 0.5× 324 0.7× 137 0.8× 66 0.7× 98 1.8× 68 592
Kwai Han Yoo South Korea 15 210 0.4× 270 0.6× 183 1.0× 83 0.9× 90 1.7× 50 588
Francesca Mazzoni Italy 18 470 0.9× 568 1.3× 178 1.0× 160 1.7× 30 0.6× 63 821
Jinhyun Cho South Korea 14 185 0.4× 498 1.1× 126 0.7× 62 0.6× 55 1.0× 37 775
Sarah Sammons United States 16 399 0.8× 466 1.0× 119 0.7× 168 1.8× 97 1.8× 92 706

Countries citing papers authored by Anna Wrona

Since Specialization
Citations

This map shows the geographic impact of Anna Wrona's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Wrona with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Wrona more than expected).

Fields of papers citing papers by Anna Wrona

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Wrona. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Wrona. The network helps show where Anna Wrona may publish in the future.

Co-authorship network of co-authors of Anna Wrona

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Wrona. A scholar is included among the top collaborators of Anna Wrona based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Wrona. Anna Wrona is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nishio, Makoto, Yi‐Long Wu, Fabrice Barlési, et al.. (2024). Health-related quality of life (HRQoL) results for adjuvant alectinib vs chemotherapy in patients with resected ALK+ non-small cell lung cancer (NSCLC): Data from ALINA.. Journal of Clinical Oncology. 42(16_suppl). 8006–8006. 1 indexed citations
2.
3.
Thallinger, Christiane, Gabriella Fábián, Laurenţia Galeş, et al.. (2022). Establishment of a virtual transborder tumor board for cancer patients in Central and Southeastern Europe. Wiener klinische Wochenschrift. 134(19-20). 697–704. 4 indexed citations
4.
5.
Wrona, Anna, et al.. (2022). A Protocol for the Non-invasive Method of Ultrasound Separation During the Sociosexual Vocal-Non-contact Model in Rats. Frontiers in Behavioral Neuroscience. 16. 910591–910591. 2 indexed citations
6.
Wrona, Anna, Rafał Dziadziuszko, & Jacek Jassem. (2021). Combining radiotherapy with targeted therapies in non-small cell lung cancer: focus on anti-EGFR, anti-ALK and anti-angiogenic agents. Translational Lung Cancer Research. 10(4). 2032–2047. 25 indexed citations
7.
Wrona, Anna & F. Mornex. (2021). Hypofractionation in Early Stage Non-Small Cell Lung Cancer. Seminars in Radiation Oncology. 31(2). 97–104. 5 indexed citations
8.
Kowalski, Dariusz M., Grzegorz Czyżewicz, Maciej Bryl, et al.. (2020). Effectiveness of Osimertinib in Patients with Lung Adenocarcinoma in Clinical Practice—The Expanded Drug Access Program in Poland. Advances in respiratory medicine. 88(3). 189–196. 1 indexed citations
9.
Wrona, Anna. (2019). Management of CNS disease in ALK-positive non-small cell lung cancer: Is whole brain radiotherapy still needed?. Cancer/Radiothérapie. 23(5). 432–438. 14 indexed citations
10.
Lewicka, Ewa, et al.. (2018). Cardiovascular complications after radiotherapy. Cardiology Journal. 27(6). 836–847. 29 indexed citations
11.
Wrona, Anna. (2018). Role of immunotherapy in stage III nonsmall cell lung cancer. Current Opinion in Oncology. 31(1). 18–23. 11 indexed citations
12.
Wrona, Anna, Rafał Dziadziuszko, & Jacek Jassem. (2018). Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors. Cancer Treatment Reviews. 71. 59–67. 35 indexed citations
13.
Gadgeel, Shirish M., Solange Peters, Tony Mok, et al.. (2018). Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Annals of Oncology. 29(11). 2214–2222. 215 indexed citations
14.
15.
Dziadziuszko, Rafał, Anh T. Le, Anna Wrona, et al.. (2016). An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer. Journal of Thoracic Oncology. 11(8). 1273–1281. 63 indexed citations
16.
17.
18.
Peters, Solange, Walter Weder, Urania Dafni, et al.. (2014). Lungscape: Resected Non–Small-Cell Lung Cancer Outcome by Clinical and Pathological Parameters. Journal of Thoracic Oncology. 9(11). 1675–1684. 26 indexed citations
19.
Wrona, Anna & Jacek Jassem. (2009). The new TNM classification in lung cancer. Oncology in Clinical Practice. 5(6). 250–260. 2 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Joan Lucca Breakdown of academic impact, for papers by Karin Holmskov Hansen Breakdown of academic impact, for papers by Chiara Bennati Breakdown of academic impact, for papers by Fernando C. Santini Breakdown of academic impact, for papers by Sasja F. Mulder Breakdown of academic impact, for papers by Nuria Kotecki Breakdown of academic impact, for papers by Kwai Han Yoo Breakdown of academic impact, for papers by Francesca Mazzoni Breakdown of academic impact, for papers by Jinhyun Cho Breakdown of academic impact, for papers by Sarah Sammons
Rankless by CCL
2026